ASH: New data reinforce benefit of Roche's Hemlibra for babies with severe hemophilia A

At this year’s American Society of Hematology (ASH) Annual Meeting, Swiss pharma giant Roche (ROG: SIX) announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra (emicizumab) in previously untreated or minimally treated infants with severe hemophilia A without factor VIII inhibitors.

Results showed that Hemlibra achieved meaningful bleed control in babies up to 12 months of age, and was seen to be well tolerated.

“Hemophilia A can have a devastating impact on any patient, but this is especially true for infants, where the emotional and physical stress due to frequent hospital visits, treatment administration and other worries can be distressing for babies and their parents and caregivers,” said Dr Steven Pipe, professor of pediatrics and pathology at the University of Michigan.